News
12-08-2014, 11:30 AM
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
More... (http://www.news-medical.net/news/20141208/Amgens-XGEVA-(denosumab)-receives-FDA-approval-for-treatment-of-hypercalcemia-of-malignancy.aspx)
More... (http://www.news-medical.net/news/20141208/Amgens-XGEVA-(denosumab)-receives-FDA-approval-for-treatment-of-hypercalcemia-of-malignancy.aspx)